People | July 10, 2024
AbbVie appoints Roopal Thakkar as EVP, Research & Development and Chief Scientific Officer
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Dyslipidemia is a critical risk factor for cardiovascular diseases
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,
Ibara will drive AI-powered clinical research innovation
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Subscribe To Our Newsletter & Stay Updated
